<div id="readability-page-1"><div><p>Changchun BCHT Biotechnology Co. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 474.44 million compared to CNY 1,026.01 million a year ago.</p><p>Net loss was CNY 158.25 million compared to net income of CNY 244.37 million a year ago. Basic loss per share from continuing operations was CNY 0.38 compared to basic earnings per share from continuing operations of CNY 0.59 a year ago. Diluted loss per share from continuing operations was CNY 0.38 compared to diluted earnings per share from continuing operations of CNY 0.59 a year ago.</p></div></div>

百克生物

<p>長春百克生物科技有限公司報告截至 2025 年 9 月 30 日的九個月內盈利大幅下降。銷售額從去年同期的 10.26 億元降至 4.7444 億元。公司面臨 1.5825 億元的淨虧損，而去年同期則實現了 2.4437 億元的淨利潤。持續經營業務的基本和攤薄每股虧損均為 0.38 元，較去年同期每股盈利 0.59 元下降</p>

長春百克生物技術有限公司報告截至2025年9月30日的九個月財務業績